investor update, page-9

if the interim results remain positive and increasingly beneficial to recipientsof the ventrassist - I can't see why the FDA wouldn't grant an extension if this has been the case for Thoratec.
It would definitely be the way to go (imo), esp now that there are several up and coming players which (if their product is equally as effective) may be preferred over an FDA approved and fully commercialised product (because a device in trials is heavily subsidised and supported by the company). I reckon that it would be beneficial for VCR to remain under trial conditions until they are FDA approved and well-known and accepted in the market.
Its going to be another few years - no doubt there will be another (hopefully small) raising, but if the momentum they speak of is translating to genuine market appreciation and acceptance.....and they have the skills to communicate this to SHs.....oops, sorry - moving into fantasyland!
Looking for a re-entry in the next couple of months